In a recent development, Actelion Pharmaceuticals Ltd. has come forward arguing that it is safeguarded against antitrust litigation over its hypertension medication, Tracleer, due to federal rules surrounding the distribution of potentially hazardous drugs. Actelion posits that it was necessary to withhold samples from potential generic competitors until such competitors could present the correct safety certification for reference.
Ideally, this move tightens controls surrounding the drug’s distribution, prioritizing patient safety. These precautions are necessary due to the potential health risks associated with Tracleer, necessitating stringent checks before its distribution, especially to generics.
However, this move has been speculated by some industry observers to limit competition in the pharmaceutical sector, raising questions about the balance between safety regulations and free market competition rules.
For more details on Actelion’s stance and arguments, check out Bryan Koenig’s piece at Law360 here.
As the legal scenario unfolds, it will be interesting to see how both federal rules and antitrust laws interact in the pharmaceutical arena, shaping future precedents.